Assessment of liver tumor response to therapy: Role of quantitative imaging

Radiographics

Volumn 33, Issue 6, 2013, Pages 1781-1800

  Gonzalez Guindalini, Fernanda D ^a   Botelho, Marcos P F ^a   Harmath, Carla B ^a   Sandrasegaran, Kumaresan ^b   Miller, Frank H ^a   Salem, Riad ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DIAGNOSTIC IMAGING; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; HUMANS; LIVER NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84885346753     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.336135511     Document Type: Article

References (76)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
2. Figueiras RG, Padhani AR, Goh VJ, et al. Novel oncologic drugs: what they do and how they affect images. RadioGraphics 2011;31(7):2059-2091.
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48(4): 1312-1327.
4. 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008;28(1):81-99.
5. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006;6:S126-S130.
6. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 2008;26(8):1346-1354.
7. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
8. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, 1979; http://whqlibdoc.who.int/publications/9241700483.pdf.
9. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412-7420.
10. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist: a review article on the modified RECIST guideline. Eur Radiol 2010;20(6):1456-1467.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
12. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
13. Mazumdar M, Smith A, Debroy PP, Schwartz LH. A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol 2005;58(2): 150-153.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
15. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195(2):281-289.
16. Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST versions 1.1 and 1.0. RadioGraphics 2011;31(7):2093-2105.
17. Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011;18(12): 1555-1560.
18. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9:208.
19. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-2344.
20. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344(14):1052-1056.
21. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183(6): 1619-1628.
22. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759.
23. Chung WS, Park MS, Shin SJ, et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol 2012;199(4):809-815.
24. 90Y help predict metabolic activity at FDG PET? Radiology 2010;255(1): 164-172.
25. Chalian H, Tochetto SM, Töre HG, Rezai P, Yaghmai V. Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. Radiology 2012;262(3):853-861.
26. Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg 2007;205(1):108-123.
27. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list: impact on transplantability and recurrence rate. J Hepatol 2013;58(3):609-618.
28. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
29. Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001;221(2):447-454.
30. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. RadioGraphics 2008;28 (2):379-390; discussion 390-392.
31. Kudo M, Kubo S, Takayasu K, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res 2010;40(7): 686-692.
32. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3): 616-623.
33. Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141(2):526-535, 535. e1-e2.
34. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262(2):708-718.
35. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55(6):1309-1316.
36. Prajapati HJ, Spivey JR, Hanish SI, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013;24(4):965-973.
37. Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and a-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012;83(4):192-200.
38. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118(1):147-156.
39. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000;175(3): 699-704.
40. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 2008;34(4):892-897.
41. Hellman RS, Krasnow AZ, Sudakoff GS. Positron emission tomography for staging and assessment of tumor response of hepatic malignancies. Semin Intervent Radiol 2006;23(1):21-32.
42. Kim BK, Kang WJ, Kim JK, et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011;117(20): 4779-4787.
43. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S-150S.
44. Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P. Treatment response classification of liver metastatic disease evaluated on imaging: are RECIST unidimensional measurements accurate? Eur Radiol 2009;19(7):1809-1816.
45. Welsh JL, Bodeker K, Fallon E, Bhatia SK, Buatti JM, Cullen JJ. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg 2012;204(5):580-585.
46. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques-initial observations. Radiology 2002;225 (2):416-419.
47. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73(875):1178-1184.
48. Lin M, Pellerin O, Bhagat N, et al. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol 2012;23(12):1629-1637.
49. Monsky WL, Garza AS, Kim I, et al. Treatment planning and volumetric response assessment for yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. Cardiovasc Intervent Radiol 2011;34(2):306-318.
50. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181(3): 708-710.
51. Padhani AR, Koh DM. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011;19(1):181-209.
52. Anzidei M, Napoli A, Zaccagna F, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011;35(6):690-696.
53. Heijmen L, Ter Voert EE, Nagtegaal ID, et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 2013;23(3):748-756.
54. Wagner M, Doblas S, Daire JL, et al. Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 2012;264(2): 464-472.
55. Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009;193(4):W301-W307.
56. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(1):49-56.
57. Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 2012;264(1):285-294.
58. Kim SY, Lee SS, Byun JH, et al. Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 2010;255(3):815-823.
59. Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2013;58 (1):169-177.
60. Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008;14(37):5738-5743.
61. Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011;55(4): 858-865.
62. Miyazaki K, Orton MR, Davidson RL, et al. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 2012;263(1):139-148.
63. Messiou C, Orton M, Ang JE, et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology 2012;265(2): 426-436.
64. García-Figueiras R, Goh VJ, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 2013;200(1):8-19.
65. Ng CS, Chandler AG, Wei W, et al. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011;260(3):762-770.
66. Qayyum A. MR spectroscopy of the liver: principles and clinical applications. RadioGraphics 2009;29 (6):1653-1664.
67. Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 2006; 21(4):258-264.
68. Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 2004;19(5): 598-604.
69. Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995;269(5232): 1854-1857.
70. Sinkus R, Tanter M, Xydeas T, Catheline S, Bercoff J, Fink M. Viscoelastic shear properties of in vivo breast lesions measured by MR elastography. Magn Reson Imaging 2005;23(2):159-165.
71. Glaser KJ, Manduca A, Ehman RL. Review of MR elastography applications and recent developments. J Magn Reson Imaging 2012;36(4):757-774.
72. Bharat S, Techavipoo U, Kiss MZ, Liu W, Varghese T. Monitoring stiffness changes in lesions after radiofrequency ablation at different temperatures and durations of ablation. Ultrasound Med Biol 2005;31 (3):415-422.
73. Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features-preliminary experience. Radiology 2012;262(3):884-893.
74. Mason RJ, Abdolell M, Trottier G, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 2011;59(5):863-867.
75. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007;242(2):555-562.
76. Chalian H, Töre HG, Rezai P, Bentrem DJ, Yaghmai V. MDCT evaluation of the growth kinetics of serous and benign mucinous cystic neoplasms of the pancreas. Cancer Imaging 2011;11:116-122.